HK1251612A1 - 包含2a肽的重組載體 - Google Patents
包含2a肽的重組載體Info
- Publication number
- HK1251612A1 HK1251612A1 HK18110849.2A HK18110849A HK1251612A1 HK 1251612 A1 HK1251612 A1 HK 1251612A1 HK 18110849 A HK18110849 A HK 18110849A HK 1251612 A1 HK1251612 A1 HK 1251612A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- peptide
- recombinant vectors
- recombinant
- vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70507—CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562214884P | 2015-09-04 | 2015-09-04 | |
PCT/US2016/049947 WO2017040815A1 (en) | 2015-09-04 | 2016-09-01 | Recombinant vectors comprising 2a peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1251612A1 true HK1251612A1 (zh) | 2019-02-01 |
Family
ID=58188345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18110849.2A HK1251612A1 (zh) | 2015-09-04 | 2018-08-23 | 包含2a肽的重組載體 |
Country Status (13)
Country | Link |
---|---|
US (1) | US11279949B2 (zh) |
EP (1) | EP3325633A4 (zh) |
JP (1) | JP2018526007A (zh) |
KR (1) | KR20180048743A (zh) |
CN (1) | CN108138201A (zh) |
AU (1) | AU2016317936A1 (zh) |
CA (1) | CA2996797A1 (zh) |
EA (1) | EA201890640A1 (zh) |
HK (1) | HK1251612A1 (zh) |
IL (1) | IL257819A (zh) |
MX (1) | MX2018002744A (zh) |
PH (1) | PH12018500477A1 (zh) |
WO (1) | WO2017040815A1 (zh) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11279949B2 (en) * | 2015-09-04 | 2022-03-22 | Denovo Biopharma Llc | Recombinant vectors comprising 2A peptide |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
JP2021508490A (ja) * | 2017-12-15 | 2021-03-11 | フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー | 環状ポリリボヌクレオチドを含む組成物及びその使用 |
EA202092807A1 (ru) * | 2018-05-30 | 2021-04-08 | Инститьют Фор Рисерч Ин Байомедисин | Конструирование в-лимфоцитов путем использования эндогенной индуцируемой активацией цитидиндезаминазы |
WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
CN109022374B (zh) * | 2018-08-16 | 2021-05-14 | 华中农业大学 | 一种塞内卡谷病毒重组质粒、重组病毒及构建方法 |
JP2022507268A (ja) * | 2018-11-13 | 2022-01-18 | デノボ バイオファーマ エルエルシー | 結合ドメインおよび分泌可能なペプチドの遺伝子を含む組換えベクター |
US20210047425A1 (en) | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
JP7398556B2 (ja) | 2019-09-30 | 2023-12-14 | ギリアード サイエンシーズ, インコーポレイテッド | Hbvワクチン及びhbvを治療する方法 |
WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
WO2022036068A1 (en) | 2020-08-13 | 2022-02-17 | A2 Biotherapeutics, Inc. | Gene fusions for control of genetically modified cells |
KR102424707B1 (ko) * | 2020-10-12 | 2022-07-25 | 전북대학교산학협력단 | 표적단백질발현을 증가시킨 진핵세포질 내 다중항원발현용 재조합벡터 및 진핵세포 내 벡터전달시스템용 살모넬라 티피뮤리움의 조합 조성물 |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
TW202332694A (zh) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | 血清半衰期延長之pd-l1結合多肽 |
CN113999873B (zh) * | 2021-12-31 | 2022-05-20 | 北京市疾病预防控制中心 | 一种基因修饰的非人动物的构建方法及其应用 |
WO2023154749A2 (en) * | 2022-02-09 | 2023-08-17 | The Regents Of The University Of California | In vitro and in vivo protein translation via in situ circularized rnas |
CN114478713B (zh) * | 2022-02-21 | 2023-03-28 | 江苏蒙彼利生物科技有限公司 | 一种cmv包膜蛋白包装慢病毒载体及其应用 |
WO2024036155A2 (en) * | 2022-08-09 | 2024-02-15 | Asimov Inc. | Split recombinases having inducible recombinase activity |
CN116286993A (zh) * | 2023-03-01 | 2023-06-23 | 武汉科技大学 | 一种HIV-tat致神经损伤模型的建立方法及其用途 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08511156A (ja) | 1993-04-06 | 1996-11-26 | アメリカ合衆国 | テナガザル白血球ウイルスベースのレトロウイルスベクター |
US20030157070A1 (en) | 1994-12-30 | 2003-08-21 | Jolly Douglas J. | High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations |
US6117681A (en) | 1995-03-29 | 2000-09-12 | Bavarian Nordic Research Inst. A/S | Pseudotyped retroviral particles |
US20030026789A1 (en) | 1995-05-03 | 2003-02-06 | Richard J. Gregory | Gene therapy using replication competent targeted adenoviral vectors |
US5912167A (en) * | 1995-06-06 | 1999-06-15 | Wisconsin Alumni Research Foundation | Autocatalytic cleavage site and use thereof in a protein expression vector |
AU1334999A (en) | 1997-10-20 | 1999-05-10 | Universita Degli Studi Di Padova | A packaging cell line producing siv-pseudotyped mlv |
FR2773561A1 (fr) | 1998-01-15 | 1999-07-16 | Centre Nat Rech Scient | Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus |
US6451304B1 (en) | 1998-03-09 | 2002-09-17 | The Regents Of The University Of California | Method for retrovirus vector production by separated gag and pol expression |
EP1076714A1 (en) | 1998-04-29 | 2001-02-21 | Oklahoma Medical Research Foundation | Construction of retroviral producer cells from adenoviral and retroviral vectors |
US7001733B1 (en) | 1998-05-12 | 2006-02-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement |
AU4089899A (en) | 1998-05-20 | 1999-12-06 | University Of Tennessee Research Corporation, The | Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy |
US6264940B1 (en) | 1998-08-05 | 2001-07-24 | The Research Foundation Of State University Of New York | Recombinant poliovirus for the treatment of cancer |
US6899871B2 (en) | 1998-10-01 | 2005-05-31 | University Of Southern California | Gene delivery system and methods of use |
WO2000018240A1 (en) | 1998-10-01 | 2000-04-06 | University Of Southern California | Gene delivery system and methods of use |
US6576463B1 (en) | 1999-01-15 | 2003-06-10 | The Regents Of The University Of California | Hybrid vectors for gene therapy |
AU4559800A (en) | 1999-04-29 | 2000-11-17 | Aarhus Universitet | Expression of heterologous genes from an ires translational cassette in retroviral vectors |
GB2368846B (en) | 1999-07-08 | 2004-08-25 | Univ California | Isolated Jaagsiekte retroviruses (JSRV), gene delivery vectors, and methods of use |
US8163893B2 (en) | 2006-02-15 | 2012-04-24 | The Regents Of The University Of Caifornia | Pseudotyped retroviral vectors and methods of use thereof |
WO2001040488A1 (en) | 1999-11-30 | 2001-06-07 | Novartis Ag | Increased transgene expression in retroviral vectors having scaffold attachment region |
US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
WO2002022663A2 (en) | 2000-09-18 | 2002-03-21 | Maxygen, Inc. | Stress resistant retroviruses |
WO2002042482A2 (en) | 2000-11-27 | 2002-05-30 | Chiron Corporation | Functional lentiviral vector from an mlv-based backbone |
WO2002061104A2 (en) | 2001-01-30 | 2002-08-08 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Hybrid adenoviral vector |
DE10111433A1 (de) | 2001-03-09 | 2002-09-19 | Bundesrepublik Deutschland Let | Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen |
JP2002335965A (ja) | 2001-05-14 | 2002-11-26 | Japan Science & Technology Corp | 細胞特異的発現複製ベクター |
DE10143237A1 (de) | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente) |
WO2003023015A2 (en) | 2001-09-13 | 2003-03-20 | California Institute Of Technology | Method for expression of small antiviral rna molecules within a cell |
FR2832424B1 (fr) | 2001-11-20 | 2004-09-24 | Genethon Iii | Plasmide chimere comprenant un genome retroviral replicatif et utilisations |
AU2003206815A2 (en) | 2002-02-01 | 2003-09-02 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with PODs |
JP2005518793A (ja) * | 2002-02-28 | 2005-06-30 | アイコニックス ファーマシューティカルズ インコーポレイテッド | 薬剤サイン |
MXPA05000647A (es) | 2002-07-17 | 2005-03-31 | Squibb Bristol Myers Co | Mamiferos no humanos transgenicos que expresan un acido nucleico reportero bajo regulacion de los elementos de respuesta de androgenos. |
WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
WO2005118802A2 (en) | 2004-06-03 | 2005-12-15 | The Regents Of The University Of California | Targeting pseudotyped retroviral vectors |
US20070003522A1 (en) | 2004-07-08 | 2007-01-04 | Albritton Lorraine M | Methods and compositions for improved retroviral gene and drug delivery |
EP1819735A1 (en) | 2004-11-04 | 2007-08-22 | Pfizer Products Inc. | Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
JP2008521405A (ja) | 2004-11-24 | 2008-06-26 | ナノヴェクター・リミテッド | ウイルスベクター |
US7968698B2 (en) | 2005-05-25 | 2011-06-28 | The Regents Of The University Of California | Optimized core promoters and uses thereof |
US20090053295A1 (en) | 2005-10-01 | 2009-02-26 | Charles Stout | Regulatable fusion promoters |
US8034355B2 (en) | 2005-10-07 | 2011-10-11 | Presidents And Fellows Of Harvard College | Attenuated nonsegmented negative-sense RNA viruses with reduced mRNA cap methyltransferase activity comprising mutations within conserved domain VI of the large polymerase |
EP1795596A1 (en) | 2005-12-08 | 2007-06-13 | Ganymed Pharmaceuticals AG | Composition and methods for therapy and diagnosis of cancer |
EP2004677A2 (en) | 2006-03-17 | 2008-12-24 | Aarhus Universitet | Chimeric viral envelopes |
EP2049659A1 (de) * | 2006-07-24 | 2009-04-22 | AB Enzymes GmbH | Vektorkonstrukte und verfahren zur expression und sekretion von polypeptiden in filamentösen pilzen unter verwendung einer selbstprozessierenden 2a-spaltstelle |
WO2008151633A2 (en) | 2007-06-15 | 2008-12-18 | Skau Aps | Vectors for vaccines against lentivirus infections |
WO2009128056A2 (en) * | 2008-04-18 | 2009-10-22 | University College Cork - National University Of Ireland, Cork | A method for screening compounds |
CA3060170A1 (en) * | 2008-06-13 | 2009-12-17 | Whitehead Institute For Biomedical Research | Programming and reprogramming of cells |
MX337213B (es) | 2008-06-30 | 2016-02-17 | Tocagen Inc | Formulaciones de 5-fluorocitosina y usos de las mismas. |
US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
JP5684130B2 (ja) * | 2008-09-26 | 2015-03-11 | トカジェン インコーポレーテッド | 組換えベクター |
CN101367749B (zh) * | 2008-09-28 | 2013-04-24 | 中国医学科学院医药生物技术研究所 | 一组胺基苯酰衍生物及其制备方法和应用 |
CA2743669C (en) * | 2008-11-24 | 2018-10-16 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | High affinity t cell receptor and use thereof |
CN101532030A (zh) * | 2009-04-21 | 2009-09-16 | 中国科学院广州生物医药与健康研究院 | 一种na片段携带外源基因的重组流感病毒载体及其制备方法和应用 |
ES2718546T3 (es) * | 2009-06-17 | 2019-07-02 | Tocagen Inc | Células productoras para vectores retrovirales de replicación competente |
CN101709084B (zh) * | 2009-11-26 | 2012-07-04 | 中国科学院广州生物医药与健康研究院 | 优化的串连细胞因子及其在诱导多能性干细胞中的应用 |
CN103237894A (zh) | 2010-08-13 | 2013-08-07 | 先锋国际良种公司 | 包含具有羟基苯丙酮酸双加氧酶(hppd)活性的序列的组合物和方法 |
JP6419706B2 (ja) * | 2012-10-25 | 2018-11-07 | トカジェン インコーポレーテッド | ミニプロモーターカセットを含むレトロウイルスベクター |
US20150086509A1 (en) * | 2013-09-25 | 2015-03-26 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating cancer using interferon and mapk pathway inhibitor |
GB201405845D0 (en) * | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
GB201507104D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
CN104946686A (zh) * | 2015-05-29 | 2015-09-30 | 广东大华农动物保健品股份有限公司 | 用于表达猪流行性腹泻蛋白中m蛋白、n蛋白和s1蛋白的重组质粒及其构建方法和应用 |
US11279949B2 (en) * | 2015-09-04 | 2022-03-22 | Denovo Biopharma Llc | Recombinant vectors comprising 2A peptide |
GB201812474D0 (en) * | 2018-07-31 | 2018-09-12 | Autolus Ltd | Nucleic acid construct |
CN110564772B (zh) * | 2019-04-03 | 2022-07-05 | 安泰吉(北京)生物技术有限公司 | 改造宿主细胞基因组的方法及其用途 |
-
2016
- 2016-09-01 US US15/757,292 patent/US11279949B2/en active Active
- 2016-09-01 KR KR1020187008093A patent/KR20180048743A/ko unknown
- 2016-09-01 EA EA201890640A patent/EA201890640A1/ru unknown
- 2016-09-01 AU AU2016317936A patent/AU2016317936A1/en not_active Abandoned
- 2016-09-01 CA CA2996797A patent/CA2996797A1/en not_active Abandoned
- 2016-09-01 JP JP2018511704A patent/JP2018526007A/ja active Pending
- 2016-09-01 EP EP16842998.3A patent/EP3325633A4/en not_active Withdrawn
- 2016-09-01 WO PCT/US2016/049947 patent/WO2017040815A1/en active Application Filing
- 2016-09-01 MX MX2018002744A patent/MX2018002744A/es unknown
- 2016-09-01 CN CN201680050920.1A patent/CN108138201A/zh active Pending
-
2018
- 2018-03-01 IL IL257819A patent/IL257819A/en unknown
- 2018-03-05 PH PH12018500477A patent/PH12018500477A1/en unknown
- 2018-08-23 HK HK18110849.2A patent/HK1251612A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2996797A1 (en) | 2017-03-09 |
EP3325633A1 (en) | 2018-05-30 |
EP3325633A4 (en) | 2019-01-16 |
US20180251786A1 (en) | 2018-09-06 |
AU2016317936A1 (en) | 2018-03-08 |
EA201890640A1 (ru) | 2018-09-28 |
CN108138201A (zh) | 2018-06-08 |
KR20180048743A (ko) | 2018-05-10 |
JP2018526007A (ja) | 2018-09-13 |
IL257819A (en) | 2018-04-30 |
PH12018500477A1 (en) | 2018-09-10 |
MX2018002744A (es) | 2018-04-13 |
US11279949B2 (en) | 2022-03-22 |
WO2017040815A1 (en) | 2017-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1251612A1 (zh) | 包含2a肽的重組載體 | |
IL275298B1 (en) | Mitochondria-targeted peptides | |
HK1254601A1 (zh) | 新型肽 | |
GB201607534D0 (en) | Peptides | |
GB201520536D0 (en) | Peptides | |
IL272655A (en) | Recombinant adeno-associated vectors | |
GB201604468D0 (en) | Peptides | |
GB201520545D0 (en) | Peptides | |
GB201520546D0 (en) | Peptides | |
GB201506316D0 (en) | Novel peptide | |
GB201520539D0 (en) | Peptides | |
GB201520567D0 (en) | Peptides | |
GB201520544D0 (en) | Peptides | |
GB201520543D0 (en) | Peptides | |
GB201520550D0 (en) | Peptides | |
GB201520541D0 (en) | Peptides | |
GB201612150D0 (en) | Modified peptide | |
GB201607535D0 (en) | Peptides | |
GB201520548D0 (en) | Peptides | |
GB201520542D0 (en) | Peptides | |
GB201719520D0 (en) | Neuroprotectvie peptide | |
GB201715378D0 (en) | Peptides | |
GB201715379D0 (en) | Peptides | |
GB201711620D0 (en) | Peptides | |
GB201707837D0 (en) | Peptides |